Login / Signup

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.

Jingshan HoValerie HeongWei Peng YongRoss SooCheng Ean CheeAndrea WongRaghav SundarYee Liang ThianAnil GopinathanMei Yan PangPriscillia KoeSanthiay Nathan JerajPhyu Pyar SoeMu Yar SoeTiffany TangMatthew C H NgDavid W M TaiTira J Y TanHongmei XuHua ChangYosef LandesmanJatin ShahSharon ShachamSoo Chin LeeDaniel S W TanBoon Cher GohDavid S P Tan
Published in: Therapeutic advances in medical oncology (2022)
twice a week given 2 out of 3 weeks. A 1-week drug holiday was needed as our patients could not tolerate the current approved continuous dosing regimens because of persistent grade 3 fatigue, anorexia and hyponatremia.
Keyphrases